Open AccessFLT-PET At 6 Weeks Predicts Response Assessed by CT at 12 Weeks in Melanoma Patients Treated With Pembrolizumab
Author(s) -
Randy Yeh,
Megan H. Trager,
Emanuelle M. Rizk,
Grace G. Finkel,
Luke W. Barker,
Richard D. Carvajal,
Larisa J. Geskin,
Gary K. Schwartz,
Lawrence H. Schwartz,
Laurent Dercle,
Yvonne M. Saenger
Publication year - 2020
Publication title -
clinical nuclear medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.637
H-Index - 57
eISSN - 1536-0229
pISSN - 0363-9762
DOI - 10.1097/rlu.0000000000002967
Subject(s) - medicine , nuclear medicine , pembrolizumab , response evaluation criteria in solid tumors , bone marrow , melanoma , pet ct , standardized uptake value , progressive disease , positron emission tomography , cancer , chemotherapy , immunotherapy , cancer research
Investigate the ability of F-fluorothymidine (FLT) PET combined with CT at 6 weeks to predict treatment response at 12 weeks after treatment with pembrolizumab.